Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohn's Disease and Ulcerative Colitis in the United States.
Huge market for this drug in IBD and potentially in liver and bowel transplantation. Annual sales could blow past 1 billion. IMO Takeda has a strong pipeline and is cheap cheap cheap.
Sentiment: Strong Buy
There seems to be a couple Takeda symbols. Is this the one we are moving to now?
are we takeda now?...they deleted everything...wow
American Eagle Hopes to Soar
Digital landlord promises a disaster-proof cloud
Crafting the perfect virtual holiday card